RVC Biofund

In June 2010 the Board of Directors of RVC has approved the Conceptual Framework of RVC Biofund. In early 2011, the fund started its operations. The Biofund was necessitated by a low share of Russian innovative drugs, amounting today to less than 1%. With virtually zero infrastructure to develop biopharma and medical start-ups, foreign services devour 50% to 80% of Russian investment resources. To remedy this, RVC BioFund will be investing capital into service companies of this cluster and biotech start-ups. Additionally, it will be launching an ecosystem to generate and incubate as many biotech projects as possible. The Fund focus covers innovative biopharma companies and service companies providing contract, laboratory, analytical and consulting services to biotechnological, pharmaceutical and medical companies.